Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9432048rdf:typepubmed:Citationlld:pubmed
pubmed-article:9432048lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:9432048lifeskim:mentionsumls-concept:C0013018lld:lifeskim
pubmed-article:9432048lifeskim:mentionsumls-concept:C0005841lld:lifeskim
pubmed-article:9432048lifeskim:mentionsumls-concept:C0023473lld:lifeskim
pubmed-article:9432048lifeskim:mentionsumls-concept:C0023516lld:lifeskim
pubmed-article:9432048lifeskim:mentionsumls-concept:C0149615lld:lifeskim
pubmed-article:9432048lifeskim:mentionsumls-concept:C0035020lld:lifeskim
pubmed-article:9432048lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:9432048lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:9432048lifeskim:mentionsumls-concept:C1521991lld:lifeskim
pubmed-article:9432048lifeskim:mentionsumls-concept:C0022702lld:lifeskim
pubmed-article:9432048lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:9432048lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:9432048lifeskim:mentionsumls-concept:C1521828lld:lifeskim
pubmed-article:9432048lifeskim:mentionsumls-concept:C1879316lld:lifeskim
pubmed-article:9432048lifeskim:mentionsumls-concept:C0332154lld:lifeskim
pubmed-article:9432048pubmed:issue4lld:pubmed
pubmed-article:9432048pubmed:dateCreated1998-1-23lld:pubmed
pubmed-article:9432048pubmed:abstractTextWe have assessed the molecular response of 30 consecutive patients with chronic myeloid leukaemia (CML) treated for relapse after allogeneic bone marrow transplantation (BMT) by donor leucocyte transfusions (DLT). Response was evaluated by qualitative nested and quantitative competitive RT-PCR for BCR-ABL mRNA at various time intervals before and after DLT. The probability of attaining molecular remission at 2 years was 61% (95% CI 42-78%). Disease state at the time of DLT was significantly associated with response: molecular remission was achieved for 9/10 (90%) patients treated early (cytogenetic or molecular relapse) compared to only 8/20 (40%) patients treated late (haematological relapse; P = 0.009). The Kaplan-Meier estimates of molecular remission at 2 years post DLT for patients treated in early or late relapse were 86.6% and 47.3% respectively (P = 0.004). The median time interval from DLT to molecular remission was 11.0 months (range 2.5-32). Molecular remissions were durable for most (15/17) patients (median follow-up 21.2 months; range 0-55). Two patterns of molecular response were found: a very rapid decline after an initial lag phase or a more gradual decline over a period of several months. We conclude that molecular monitoring is a sensitive indicator of response to DLT; different kinetics of molecular response may reflect disease heterogeneity or differences in the mode of action of DLT.lld:pubmed
pubmed-article:9432048pubmed:languageenglld:pubmed
pubmed-article:9432048pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9432048pubmed:citationSubsetIMlld:pubmed
pubmed-article:9432048pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9432048pubmed:statusMEDLINElld:pubmed
pubmed-article:9432048pubmed:monthDeclld:pubmed
pubmed-article:9432048pubmed:issn0007-1048lld:pubmed
pubmed-article:9432048pubmed:authorpubmed-author:ReiterAAlld:pubmed
pubmed-article:9432048pubmed:authorpubmed-author:GoldmanJ MJMlld:pubmed
pubmed-article:9432048pubmed:authorpubmed-author:LiaSSlld:pubmed
pubmed-article:9432048pubmed:authorpubmed-author:DazziFFlld:pubmed
pubmed-article:9432048pubmed:authorpubmed-author:RaananiPPlld:pubmed
pubmed-article:9432048pubmed:authorpubmed-author:van RheeFFlld:pubmed
pubmed-article:9432048pubmed:authorpubmed-author:CrossN CNClld:pubmed
pubmed-article:9432048pubmed:authorpubmed-author:SzydloR MRMlld:pubmed
pubmed-article:9432048pubmed:authorpubmed-author:SohalJJlld:pubmed
pubmed-article:9432048pubmed:issnTypePrintlld:pubmed
pubmed-article:9432048pubmed:volume99lld:pubmed
pubmed-article:9432048pubmed:ownerNLMlld:pubmed
pubmed-article:9432048pubmed:authorsCompleteYlld:pubmed
pubmed-article:9432048pubmed:pagination945-50lld:pubmed
pubmed-article:9432048pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:9432048pubmed:meshHeadingpubmed-meshheading:9432048-...lld:pubmed
pubmed-article:9432048pubmed:meshHeadingpubmed-meshheading:9432048-...lld:pubmed
pubmed-article:9432048pubmed:meshHeadingpubmed-meshheading:9432048-...lld:pubmed
pubmed-article:9432048pubmed:meshHeadingpubmed-meshheading:9432048-...lld:pubmed
pubmed-article:9432048pubmed:meshHeadingpubmed-meshheading:9432048-...lld:pubmed
pubmed-article:9432048pubmed:meshHeadingpubmed-meshheading:9432048-...lld:pubmed
pubmed-article:9432048pubmed:meshHeadingpubmed-meshheading:9432048-...lld:pubmed
pubmed-article:9432048pubmed:meshHeadingpubmed-meshheading:9432048-...lld:pubmed
pubmed-article:9432048pubmed:meshHeadingpubmed-meshheading:9432048-...lld:pubmed
pubmed-article:9432048pubmed:meshHeadingpubmed-meshheading:9432048-...lld:pubmed
pubmed-article:9432048pubmed:year1997lld:pubmed
pubmed-article:9432048pubmed:articleTitleThe rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation.lld:pubmed
pubmed-article:9432048pubmed:affiliationDepartment of Haematology, Imperial College School of Medicine, Hammersmith Hospital, London.lld:pubmed
pubmed-article:9432048pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9432048pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9432048lld:pubmed